RxDoctor Payments Data

Ian Laxina, MD

Cardiovascular Disease · Charleston, SCNPI 1265952634

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (44.3%), food and beverage and grants — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 43.7% of the total. 2025 is the largest year on record at $9,634, 5.5 times the $1,742 reported in 2021. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,190in general payments, 2019–2025

Across 203 payments — averaging $104.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Boston Scientific$6K
  • Abbott$5K
  • Amgen$727
  • Pfizer$229
  • Astellas Pharma US Inc$198
  • plus $447 from 6 others

What the payments were for

  • Grants$4,00019%
  • Travel & lodging$9,38544%
  • Food & beverage$7,18034%
  • Education$6253%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,190 in reported general payments places this provider in the 90th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$105,153
Medicare patients
1,528
Services billed
2,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$24,894
JardianceEmpagliflozin11$10,798
Ezetimibe25$1,174
Rosuvastatin Calcium49$580
Metoprolol Succinate31$499
Isosorbide Mononitrate ErIsosorbide Mononitrate15$290
Spironolactone20$268
Atorvastatin Calcium24$242
Losartan Potassium14$232
Amlodipine Besylate28$185
Carvedilol26$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$229$24,89420 claims
Boehringer IngelheimJardiance$51$10,79811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →